Modality
ERT
MOA
SGLT2i
Target
FXIa
Pathway
Innate Imm
TTR AmyloidosisCLLPsA
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
Mar 2019
→ Mar 2027
Phase 1Current
NCT05693845
1,894 pts·PsA
2019-03→2027-03·Not yet recruiting
1,894 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-013mo awayConference· CLL
2027-03-2512mo awayInterim· PsA
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Not yet…
Catalysts
Conference
2026-07-01 · 3mo away
CLL
Interim
2027-03-25 · 12mo away
PsA
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05693845 | Phase 1 | PsA | Not yet recr... | 1894 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |